SEATTLE, May 18, 2022 /PRNewswire/ — Mozart Therapeutics, a leading developer of CD8 Treg modulators in autoimmune and inflammatory disease, today announced it will present at Digestive Disease Week® (DDW) taking place May 21-24, 2022 in San Diego, CA and virtually.
The presentation will detail Mozart’s research on the role of a novel CD8 T regulatory cell network in autoimmune diseases of the gut, including Celiac disease, Crohn’s disease and Ulcerative Colitis. This includes findings identifying the presence of the network and a mechanism by which CD8 T regulatory cells eliminate pathogenic CD4 cells.
“Our research highlights the function of CD8 regulatory T cells in suppressing pathogenic T cells and the related potential to reduce the severity of inflammatory diseases,” said Kristine Swiderek, PhD, Chief Scientific Officer at Mozart Therapeutics “The findings support our focus on the development of immune-modulating biologics to target this novel network for autoimmune and inflammatory diseases.”
Presentation details are as follows:
Title: “A Newly Discovered Regulatory CD8 T Cell Network has the Potential to Regulate and Eliminate Pathogenic CD4 T Cells in Autoimmune Mediated Digestive Disease”
Presentation number: sa1117
Session: Cell and Molecular Biology of Gastrointestinal Disorders
Date/Time: Saturday, May 21, 12:30 to 1:30 p.m., Pacific
Presenter: Kristine Swiderek, PhD, Mozart Therapeutics
The poster will be available on the Science page of the Mozart website shortly after the presentation.
About Mozart Therapeutics
Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory CD8 T regulatory cell network. The therapeutic focus of Mozart’s lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.
About CD8 Treg Modulators
CD8 Treg Modulators are disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract early events in the autoimmune inflammatory cascade. The dysregulation of this network is believed to play a key role in the pathology of autoimmune and inflammatory disease. CD8 Treg modulators are designed to restore the intrinsic functions of CD8 T regulatory cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mozart-therapeutics-to-present-on-novel-cd8-t-cell-network-at-the-2022-digestive-disease-week-ddw-conference-301549499.html
SOURCE Mozart Therapeutics
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…